Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
In Reply: We thank Drs Racoosin and Knudsen
for pointing out these important, additional safety issues that have recently
arisen. We also thank them for clarifying that oligohydrosis, not hyperhydrosis,
is the cause of rare fevers in children who receive zonisamide.
LaRoche SM, Helmers SL. Safety of Newer Antiepileptic Drugs—Reply. JAMA. 2004;291(17):2074. doi:10.1001/jama.291.17.2074-b